Literature DB >> 25398378

An update and review of the treatment of myoclonus.

Kelly Mills1, Zoltan Mari.   

Abstract

Recent advances in medications and surgical therapy for neurological disorders may offer new therapeutic options for the treatment of myoclonus. Appropriate therapy for myoclonus depends on the etiology, and in some cases, myoclonus can improve when the provoking cause is eliminated. When the underlying cause for the movements is not immediately reversible, localization, disease pathophysiology, and etiology may each play a role in determining the most appropriate symptomatic treatment of disabling myoclonic jerks. While the use of many agents is still based on small, open-label case series and anecdotes, there is a growing body of evidence from head-to-head comparative trials in several types of myoclonus that may help guide therapy. New therapies for refractory myoclonus, including sodium oxybate and even deep brain stimulation, are also being explored with increasing enthusiasm.

Entities:  

Mesh:

Year:  2015        PMID: 25398378     DOI: 10.1007/s11910-014-0512-2

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  103 in total

1.  Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A.

Authors:  A Lagueny; F Tison; P Burbaud; G Le Masson; P Kien
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

2.  Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.

Authors:  L Bataller; F Graus; A Saiz; J J Vilchez
Journal:  Brain       Date:  2001-02       Impact factor: 13.501

3.  Cognition and psychopathology in myoclonus-dystonia.

Authors:  Mirjam J van Tricht; Yasmine E M Dreissen; Danielle Cath; Joke M Dijk; Maria Fiorella Contarino; Sandra M van der Salm; Elisabeth M J Foncke; Justus L Groen; Ben Schmand; Marina A J Tijssen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-05-23       Impact factor: 10.154

4.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months.

Authors:  Tracy A Glauser; Avital Cnaan; Shlomo Shinnar; Deborah G Hirtz; Dennis Dlugos; David Masur; Peggy O Clark; Peter C Adamson
Journal:  Epilepsia       Date:  2012-11-21       Impact factor: 5.864

5.  Intrathecal baclofen for the treatment of spinal myoclonus: a case series.

Authors:  Anthony E Chiodo; April Saval
Journal:  J Spinal Cord Med       Date:  2012-01       Impact factor: 1.985

6.  Myoclonic disorders: a practical approach for diagnosis and treatment.

Authors:  Maja Kojovic; Carla Cordivari; Kailash Bhatia
Journal:  Ther Adv Neurol Disord       Date:  2011-01       Impact factor: 6.570

7.  Effects of anticonvulsants on the formation of gamma-hydroxybutyrate from gamma-aminobutyrate in rat brain.

Authors:  S R Whittle; A J Turner
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

8.  The treatment of severe action myoclonus.

Authors:  J A Obeso; J Artieda; J C Rothwell; B Day; P Thompson; C D Marsden
Journal:  Brain       Date:  1989-06       Impact factor: 13.501

9.  Psychogenic palatal tremor may be underrecognized: reappraisal of a large series of cases.

Authors:  Maria Stamelou; Tabish A Saifee; Mark J Edwards; Kailash P Bhatia
Journal:  Mov Disord       Date:  2012-03-20       Impact factor: 10.338

View more
  5 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

Review 2.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 3.  Myoclonic Disorders.

Authors:  Olaf Eberhardt; Helge Topka
Journal:  Brain Sci       Date:  2017-08-14

4.  Myoclonus in older Cavalier King Charles Spaniels.

Authors:  Carina Rotter; Danielle Whittaker; Clare Rusbridge
Journal:  J Vet Intern Med       Date:  2022-03-23       Impact factor: 3.175

5.  Myoclonus generators in sialidosis.

Authors:  Felipe Vial; Patrick McGurrin; Sanaz Attaripour; Alesandra d'Azzo; Cynthia J Tifft; Camilo Toro; Mark Hallett
Journal:  Clin Neurophysiol Pract       Date:  2022-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.